The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

Hepatitis B (HBV) Patients & Caregivers – Your Help Requested re Vemlidy

Do you have HEPATITIS B or are you a CAREGIVER for someone with HBV? This is really important for you! An improved hepatitis B treatment will likely be available to Canadians soon, but first the federal government has requested us to submit a patient group review to them (CADTH) explaining whether hepatitis B patients want this new treatment, and why. What is the new hepatitis B treatment? It is tenofovir alafenamide or TAF (brand name VemlidyTM) made by

Patient input is requested by BCPharmaCare for Merck’s MK2: Zepatier (grazoprevir / elbasvir)

Zepatier™ (grazoprevir / elbasvir [± ribavirin]) Merck’s combo was approved by the FDA in January: http://www.mercknewsroom.com/news-release/prescription-medicine-news/merck-receives-fda-approval-zepatier-elbasvir-and-grazoprevi and was also approved in Canada for genotypes 1, 3 and 4 in early February: http://hepcbc.ca/2016/02/merck-receives-approval-of-zepatier-elbasvirgrazoprevir-in-canada-for-the-treatment-of-chronic-hepatitis-c-for-patients-...